It has been reported that outcomes are improved in patients with severe lupus nephritis treated with combined prednisone and intravenous cyclophosphamide, compared with those treated with prednisone alone.
These findings motivated this analysis of the economic impact of the combined therapy.
The annual expected incidence of severe lupus nephritis in the year 19% in the US was estimated to be 1,130.
A hypothetical patient cohort of this size was used as the model for the present analysis ; the costs of treatment with prednisone alone and with combined prednisone and intravenous cyclophosphamide were calculated and compared.
Mots-clés Pascal : Lupus érythémateux, Disséminé, Homme, Néphropathie, Chimiothérapie, Immunodépresseur, Association médicamenteuse, Prednisone, Cyclophosphamide, Analyse coût, Aspect économique, Etats Unis, Amérique du Nord, Amérique, Peau pathologie, Tissu conjonctif pathologie, Maladie système, Maladie autoimmune, Immunopathologie, Appareil urinaire pathologie, Rein pathologie
Mots-clés Pascal anglais : Lupus erythematosus, Disseminated, Human, Nephropathy, Chemotherapy, Immunosuppressive agent, Drug combination, Prednisone, Cost analysis, Economic aspect, United States, North America, America, Skin disease, Connective tissue disease, Systemic disease, Autoimmune disease, Immunopathology, Urinary system disease, Renal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0551358
Code Inist : 002B02Q. Création : 09/06/1995.